Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update

Neumora Therapeutics, Inc. (NASDAQ:NMRA) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 5,986,621 shares, a drop of 20.2% from the December 31st total of 7,502,647 shares. Based on an average daily trading volume, of 3,853,615 shares, the days-to-cover ratio is presently 1.6 days. Approximately 4.9% of the shares of the stock are short sold. Approximately 4.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,853,615 shares, the days-to-cover ratio is presently 1.6 days.

Insider Activity

In related news, insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total value of $307,404.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 26.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neumora Therapeutics

Several hedge funds have recently bought and sold shares of NMRA. Jacobs Levy Equity Management Inc. bought a new position in shares of Neumora Therapeutics during the third quarter worth $1,512,000. Millennium Management LLC lifted its holdings in Neumora Therapeutics by 63.1% during the third quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock worth $3,655,000 after acquiring an additional 776,856 shares in the last quarter. AQR Capital Management LLC acquired a new position in Neumora Therapeutics in the first quarter valued at about $463,000. AlphaCore Capital LLC acquired a new position in Neumora Therapeutics in the second quarter valued at about $248,000. Finally, Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics in the second quarter worth about $183,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Down 0.5%

Shares of Neumora Therapeutics stock traded down $0.01 on Monday, hitting $1.98. 509,486 shares of the company’s stock traded hands, compared to its average volume of 2,296,352. The firm’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $1.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The stock has a market capitalization of $330.84 million, a PE ratio of -1.35 and a beta of 3.20. Neumora Therapeutics has a one year low of $0.61 and a one year high of $3.25.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, research analysts expect that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NMRA. Guggenheim raised shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. Stifel Nicolaus lifted their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Finally, Leerink Partners began coverage on Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.13.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.